Related Experiment Video

Updated: Aug 10, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

EGFR in colorectal cancer: more than a simple receptor

M Francoual1, M-C Etienne-Grimaldi, J-L Formento

  • 1Centre Antoine-Lacassagne, Nice, France.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|March 10, 2006
PubMed
Abstract

Insights

This study reveals that colorectal tumors possess both high- and low-affinity epidermal growth factor receptor (EGFR) binding sites, explaining varied treatment responses and side effects in targeted cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Targeted therapies, including those targeting the epidermal growth factor receptor (EGFR), have advanced colorectal cancer treatment.
  • Understanding tumor biology is crucial for developing effective cancer therapies.

Purpose of the Study:

  • To investigate the presence and distribution of high- and low-affinity EGFR binding sites in colorectal cancer.
  • To correlate EGFR expression patterns with clinical outcomes and treatment responses.

Main Methods:

  • Retrospective analysis of 82 colorectal cancer samples, including paired normal colon tissue.
  • Utilized a specific ligand binding assay (Scatchard Analysis) to quantify EGFR binding sites.

Main Results:

  • 78% of tumor samples showed one class of high-affinity EGFR binding sites; 22% had both high- and low-affinity sites.
  • Significant interpatient variability in EGFR site number was observed in both tumor and normal tissues.
  • A positive correlation was found between tumor and normal mucosa for high-affinity EGFR binding characteristics, suggesting common regulation.

Conclusions:

  • Findings may explain clinical efficacy of EGFR-targeted drugs in tumors with low/undetectable EGFR.
  • The results offer a potential explanation for the link between anti-EGFR drug toxicity (e.g., rash) and patient outcomes.
  • This research enhances the understanding of EGFR in colorectal cancer, potentially improving predictive tools for targeted therapy response.

More Related Videos

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...